



Sagittal View of Male Reproductive System




Coronal Section of Penis






DigitalLab3D





virtualmedicalcentre.com



Therapy of Erectile Dysfunction (ED)

B, Risk Factor Modifications

1, Diabetes Control

Level of HbA_{1c} was significantly higher with declining degrees of potency (P-value=0.003), and there was a significant association between potency degree and glycemic control (P=0.002)

1.

Glycemic control and other metabolic covariates were associated with ED risk, whereas higher level of physical activity was protective 2.

(n=203, Ø 65,5 yr, 45-74 yr.)

ED was strongly associated with depression symptoms after controlling for potential confounding factors using logistic regression.

ED is significantly associated with highly depressive symptoms, regardless of age, health habit or concomitant comorbidity. Our results demonstrate that multidisciplinary approaches are important for the successful treatment of ED.

Oral Drug Therapy With PDE 5 Inhibitors : Pharmaco ki- netic Character istics of PDE 5	TMax (min)	Onset of Action (min) Earliest >50% pt.response	T_{1/2} (h)	Duration of Efficacy h (% succesf. coitus)

Inhibitors Licensed in Europe

Drug

(Authors)

¹⁻⁴ Sildenafil 100 mg	70 (30-120)	14 20	3,82 ± 0,84	8 (85 %)
^{1,,4,5-7} Tadalafil 20 mg	120 (30-720)	16 30	17,5	36 (59 and 62 %)
^{1,4,7-10} Vardenafil 20 mg	40 (15-180)	11 25	3,94 ± 1,31	8±2 (69 %)

1.Re-counselling of the patients/couples in the appropriate use of PDE 5 inhibitors including early dose adjustment especially the use of the highest doses with **salvage rates of up to 60 %** depending on the study-population under investigation.

Regarding Efficacy and Safety of Medical Treatment of ED a broad level 1a and 1b evidence unanimously exists for the following treatment options:

• **On demand („as needed“)**

therapy:

with the **PDE 5 inhibitors** Sildenafil

(Viagra™), Tadalafil (Cialis™), Vardenafil

(Levitra™), Udenafil (Zydena™),

Avanafil (Spedra™ Stendra™), Lodenafil

(Helleva™)

Efficacy rates are between 60 and 75 %

SEP 3 Rates

depending on the investigated

populations

Medical Therapy of ED

Oral Drug Therapy With PDE 5 Inhibitors:

Drug-Related	Sildenafil 1 (n = 5.918)	Vardenafil 2 (n= 2.203)	Tadalafil3 (n = 804)
Adverse			
Events (On			
Demand			
Therapy)			
Side-effect			
Headache	14,6 %	14,5 %	14 %
Flush	14,1 %	11,1 %	4 %

Dyspepsia	6,2 %	3,7 %	10 %
Rhinitis	2,6 %	9,2 %	5 %
Back pain	0 %	0 %	6 %
Color visual disturbances	5,2 %	0 %	0 %

Intracavernous injection therapy with

•1. **PGE 1, syn. Alprostadil-**(Caverject™ , Viridal™, Edex™) 5-40µg

•2. Combination of **Papaverine/Phentolamine** (Androskat™) 15-60mg/0,5-2mg

•3. Mixture of **Papaverine/Phentolamine/PGE1 - Trimix**

(no commercial product available)

•4. Mixture of **VIP/Phentolamine** (Invicorp™) 25µg/1-2mg

Medical Therapy of ED

Porst, H: Oral Pharmacotherapy of Erectile Dysfunction and